



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	338266	Lipotropex
ARTG entry for	Medicine Listed	
Sponsor	RN Labs Pty Ltd	
Postal Address	18 / 93 Rivergate Place, MURARRIE, QLD, 4172 Australia	
ARTG Start Date	23/06/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Lipotropex

Product Type	Single Medicine Product	Effective Date	23/06/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support natural liver cleansing/detoxification processes

Aid/assist/helps digestion of fats/fatty acids/triglycerides/lipid

Maintain/support bile production

Maintain/support healthy liver function

Indication Requirements

Product presentation must not imply or refer to lowering blood lipids, blood fats and triglycerides.

Product presentation must only refer to detoxification in relation to natural body processes.

Product presentation must not imply or refer to drugs/alcohol.

Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.

Product presentation must not imply or refer to disease in any body organ, in particular the kidney or liver.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

Additional Product information

Pack Size/Poison information



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Powder

Route of Administration Oral

Visual Identification

Active Ingredients

acetyl levocarnitine hydrochloride	116.67 mg/g
ascorbic acid	41.67 mg/g
choline bitartrate	83.33 mg/g
glycine	150 mg/g
inositol	116.67 mg/g
selenomethionine	.0124 mg/g
Equivalent: selenium	.005 mg/g
Silybum marianum fruit Extract dry concentrate	83.33 mg/g
Equivalent: Silybum marianum (Dry)	5.83 g/g
taurine	166.67 mg/g

Other Ingredients (Excipients)

colloidal anhydrous silica

Flavour

glycine

Siraitia grosvenorii

Stevia rebaudiana

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary